Sam Wu

Sam Wu is a founding Managing Director of Acuris Partners, a biotechnology-focused venture capital firm. He has over 17 years of experience in life science venture capital and has invested in and/or served on the boards of over 25 startups and later stage biotechnology and medical device companies including Applied Genomic Technologies Corp (NASDAQ: AGTC), Ocular Therapeutix (NASDAQ: OCUL), Sapphire Therapeutics (acquired by Helsinn), Confluent Surgical (acquired by Tyco), and CHF Solutions (acquired by Gambro). Prior to Acuris, he was a Managing Director with MedImmune Ventures, the corporate venture capital arm of AstraZeneca, and before that, a Principal with SV Health Investors, a healthcare-focused venture capital firm with over $1 billion under management.